iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) saw a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 1,280,000 shares, a drop of 19.0% from the February 13th total of 1,580,000 shares. Approximately 3.9% of the shares of the company are short sold. Based on an average daily trading volume, of 362,400 shares, the days-to-cover ratio is presently 3.5 days.
iTeos Therapeutics Price Performance
Shares of NASDAQ ITOS traded down $0.01 during midday trading on Friday, reaching $6.88. 417,149 shares of the company traded hands, compared to its average volume of 457,145. iTeos Therapeutics has a 52 week low of $6.67 and a 52 week high of $18.75. The stock has a 50-day moving average price of $7.39 and a 200 day moving average price of $8.77. The company has a market cap of $262.77 million, a price-to-earnings ratio of -2.18 and a beta of 1.38.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts' consensus estimates of ($1.14) by $0.13. As a group, analysts expect that iTeos Therapeutics will post -3.49 EPS for the current year.
Wall Street Analyst Weigh In
ITOS has been the topic of a number of recent research reports. Wedbush reiterated an "outperform" rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and issued a $46.00 target price on shares of iTeos Therapeutics in a research note on Thursday, March 6th. JPMorgan Chase & Co. cut their target price on iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating on the stock in a research note on Thursday, March 6th. Finally, Wells Fargo & Company cut their target price on iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, March 6th.
View Our Latest Research Report on ITOS
Institutional Investors Weigh In On iTeos Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BVF Inc. IL bought a new stake in iTeos Therapeutics in the fourth quarter worth about $17,856,000. JPMorgan Chase & Co. raised its position in iTeos Therapeutics by 342.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock worth $15,888,000 after acquiring an additional 1,601,477 shares in the last quarter. Dimensional Fund Advisors LP raised its position in iTeos Therapeutics by 15.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company's stock worth $9,293,000 after acquiring an additional 163,880 shares in the last quarter. State Street Corp raised its position in iTeos Therapeutics by 21.9% in the third quarter. State Street Corp now owns 1,175,353 shares of the company's stock worth $12,000,000 after acquiring an additional 211,452 shares in the last quarter. Finally, Boxer Capital Management LLC bought a new stake in iTeos Therapeutics in the fourth quarter worth about $7,272,000. 97.16% of the stock is currently owned by institutional investors.
iTeos Therapeutics Company Profile
(
Get Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Featured Stories
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
